NCT00743067View on ClinicalTrials.gov

A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

37

Participants

Timeline

Start Date

August 9, 2006

Primary Completion Date

May 2, 2009

Study Completion Date

November 9, 2009

Conditions

Solid Tumours

Interventions

DRUG

GSK1363089 (formerly XL880)

GSK1363089 will be available as solid capsules with dose unit of 20, 100 and 200 mg. Subjects will administer GSK1363089 capsules orally

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY